GlassScriptPhysician profile
Elliot Schwarzenberger
NPI 1952568289
$15,228.83
in general payments reported to CMS, 2019-2025
48 companies · $2,169 in 2025
The $2,169 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,388 · 2020: $1,834 · 2021: $1,958 · 2022: $2,438 · 2023: $2,273 · 2024: $2,169 · 2025: $2,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,329 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,329.30 |
| Education | $281.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,815.21 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,857.45 | 2019-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,190.83 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,100.62 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $621.94 | 2019-2025 | |
| Amgen INC. | $472.62 | 2020-2023 | Amjevita, Avsola |
| Intercept Pharmaceuticals, INC. | $415.35 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $382.05 | 2019-2025 | Sucraid |
| Celgene Corporation | $378.10 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $335.79 | 2019-2024 | |
| Genzyme Corporation | $278.75 | 2022-2025 | |
| Ardelyx, INC. | $259.96 | 2022-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $229.77 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $221.41 | 2019-2023 | Zinplava, Dificid |
| Ipsen Biopharmaceuticals, INC | $206.07 | 2024-2025 | Iqirvo, Bylvay |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Schwarzenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.